A series of monoclonal antibodies was isolated which reacted with one of two major surface proteins of rhesus rotavirus. Thirty-six monoclonal antibodies immunoprecipitated the 82-kilodalton outer capsid protein, the product of the fourth gene, the viral hemagglutinin. These monoclonal antibodies exhibited hemagglutination inhibition activity and neutralized rhesus rotavirus to moderate or high titer. Three monoclonal antibodies immunoprecipitated the 38-kilodalton outer capsid glycoprotein, the eighth or ninth gene product. These three monoclonal antibodies neutralized rhesus rotavirus to high titer and also inhibited viral hemagglutination.
Rotaviruses, newly characterized members of the Reoviridae family, are an important cause of infantile diarrhea in many mammalian species, including humans (7, 33) . Unlike the mammalian reoviruses, it appears that most mammalian rotavirus strains have a restricted host range. In addition, rotaviruses exhibit a remarkable degree of tissue tropism in vivo, replicating almost exclusively in the villous tip cells of the small intestinal epithelium (30, 33) .
As part of a series of studies aimed at examining rotavirus tropism for cell and host, we have isolated a number of monoclonal antibodies directed at two major surface proteins of rhesus rotavirus (RRV). RRV was chosen for study because it grows well in tissue culture, it is serotypically identical to one of the three major human rotavirus serotypes, and we have already determined the gene-coding assignments for several important RRV functions (15, 31) . In addition, the availability of an RRV strain propagated only in primary cell culture (29) and its relative attenuation in experimental animals make this virus a promising vaccine candidate (R. Wyatt and E. Bohl, unpublished data). In this study RRV monoclonal antibodies have been used to verify gene-coding assignments for the viral hemagglutinin (gene 4) and neutralizing protein (gene 8 or 9) that were made independently by combined genotypic and phenotypic analysis of viral reassortants (15) . In addition, the monoclonal antibodies were used to investigate the antigenic relationships of the viral hemagglutinins and neutralizing proteins of a variety of separate mammalian rotavirus strains. Finally, selected monoclonal antibodies were used to demonstrate that neutralization of rotavirus can be mediated by antibody to the 82-kilodalton (kd) (the viral hemagglutinin) as well as the 38-kd protein.
MATERIALS AND METHODS Viruses. RRV strain 2 (MMU 18006) was originally obtained from N. Schmidt (29) . It was passaged in MA104 cells before use for immunization or immunoassay. Temperature-sensitive (ts) mutants of RRV were generated by cultivating the virus in the presence of 5-azacytidine (400 mg/ml) in MA104 cells, using a technique similar to that previously described (10) . Bovine rotavirus (UK strain) x RRV reassortants were isolated from MA104 cell cultures coinfected at 34WC with ts mutants of both viruses (15) . The growth yield of the coinfected cultures was plaqued at 39.5°C. Discrete plaques were picked and plaque purified twice at 39.5°C before amplification for use in solidphase immunoassays or hemagglutination inhibition (HI) assays. The UK strain was isolated by G. Woode and J. Bridger and was originally provided by T. Flewett (2). It was propagated in MA104 cells. Canine rotavirus strain CU-1 was provided by Y. Hoshino (14) . Nebraska calf diarrhea virus, bovine strain, was provided by C. Mebus. OSU porcine rotavirus was provided by E. Bohl and K. Theil. SA-11 rotavirus was provided by H. Malherbe. All rotavirus strains and reassortants were grown in MA104 cells in the presence of trypsin (0.5 ,ug/ml).
Analysis of the genotype of viral reassortants. The genotype of the UK rotavirus x RRV reassortants was 268 GREENBERG ET AL.
32P-labeled single-stranded mRNAs from both parents were synthesized in vitro by utilizing the endogenous RNA-dependent RNA polymerase present in rotaviral cores (4) . Reassortant virion double-stranded RNA was denatured by heating at 100°C for 2 min and then hybridized to 32P-labeled single-stranded RNA transcripts from either parent. The hybridization mixtures were then electrophoresed on polyacrylamide gel and autoradiographed (15) .
Immunization. Two female BALB/c mice (952 and 954) were immunized with RRV strain 2, which was partially purified by high-speed pelleting, fluorocarbon extraction, and rate zonal sedimentation through a 20 to 40% sucrose gradient (SW40 rotor; 35,000 rpm for 90 min). The fractions with the peak viral hemagglutination (HA) titer were used for immunization. Both mice were initially immunized intraperitoneally with virus mixed with an equal volume of complete Freund adjuvant. One to 2 months later virus was again administered intraperitoneally with an equal volume of incomplete Freund adjuvant. The mice were again boosted 1 to 2 months later by intravenous inoculation of complete virus in phosphate-buffered saline (PBS). Three days after the intravenous boost the mice were sacrificed and spleens were removed for fusions. At the time of sacrifice both mice had a serum HI titer of >1:640 against RRV.
Fusion of spleen and NS-1 cells. The spleen cells were suspended in Dulbecco minimal essential medium (MEM) with gentamicin and pelleted (500 rpm for 5 min). The resuspended spleen cells were counted by trypan blue exclusion and then mixed with NS-1 myeloma cells at a ratio of 10:1. The spleen cell-NS-1 cell mixture was again centrifuged (1,000 rpm for 5 min), and the supernatant was removed. The cell pellet was shaken gently, and 1 ml of 50% polyethylene glycol 1000 in Dulbecco MEM was added over a 1-min period. Over a 5-min period, 25 (26) . After an additional 1-h incubation at 37°C, plates were washed four times, and individual wells were cut with scissors and counted in a gamma counter. Negative controls consisted of wells to which virus was not added and wells to which NS-1 cell supernatant medium was added. The two types of negative control wells gave similar results. Wells with three times as many counts bound as negative controls were considered positive (positive/negative ' 3) (11) .
HA and HI assay. Viral hemagglutinins used for the HI assay (see Tables 1 and 2 ) were prepared by freezing and thawing rotavirus-infected MA104 cells when the cultures exhibited complete or almost complete cytopathic effect. Culture fluid was extracted once with an equal volume of Genetron 113 (Allied Chemical Corp.) and then spun at 2,000 rpm for 15 min. The crude viral extract in the aqueous phase was stored at 4°C and used as HA antigen for HI assay. HI assay was performed as previously described, using 2 to 4 U of hemagglutinin and human 0 or rhesus monkey erythrocytes (17) . Monoclonal antibodies were titrated by serial twofold dilution in PBS with 0.3% bovine serum albumin (17) .
Preparation of radiolabeled infected cell lysates. Viral proteins were labeled by using a modification of the method of Lee et al. (22) . MA104 monolayers were infected with virus (RRV) at a multiplicity of infection varying from 1 to 10. Virus was initially treated with trypsin (5 ,ug/ml for 1 h at 37°C). After a 1-h adsorption period, monolayers were washed and refed with Eagle MEM with glutamine and antibiotics. Eagle MEM-agarose as described before (32) . After 3 to 6 days, an agarose overlay containing neutral red was added and the plaques were counted. Negative surface proteins of RRV. From 1,000 wells initially screened by HI, 39 separate monoclonal antibodies with HI activity were eventually cloned and grown up in volume for further analysis. These monoclones formed the basis of the further studies reported here. Thirty-six of the 39 monoclonal antibodies with HI activity precipitated an 82-kd protein from RRV cell lysates (Fig. 1, lanes 3, 4 , 5, and 6, and Fig. 2, lane 3) . In addition, these monoclonal antibodies precipitated one to three less intense bands in the 70-to 75-kd range ( Fig. 1  and 2 ). The monoclonal antibodies which precipitated the 82-kd protein were titrated by HI against a variety of hemagglutinating rotaviruses. Representative data from eight of these hybridomas are shown in Table 1 . Each exhibited a high degree of homologous specificity in the HI assay. Low-level cross-reactivity with monkey SA-11 and porcine OSU rotaviruses was observed in a few instances (Table 1 , monoclone 954/145/55, for example). The monoclonal antibodies which immunoprecipitated the 82-kd protein were also assayed in a standard plaque reduction neutralization assay against RRV. Neutralizing activity was not detected in the supernatants of these monoclonal cell cultures tested at a 1:20 dilution. Because of the lack of detectable neutralizing activity in the hybridoma cell culture supernatant fluids, ascites fluids derived from mice inoculated with monoclonal antibodies to the 82-kd protein were tested by plaque reduction neutralization. The HI titers versus RRV of the ascites fluid were between 102-and 103 5-fold higher than titers of the culture fluid supernatant. Interestingly, moderate to high levels of neutralizing activity were detected when the ascites fluid was studied in a plaque reduction neutralization assay ( Table 2) . The preinoculation serum-neutralizing antibody titer of each of the mice against RRV was <1:500. In limited neutralization tests against heterologous viruses, the neutralizing activity appeared to be highly specific for the immunizing RRV strain (Table 2 , monoclone 954/23/4, for example). The neutralizing activity of these monoclonal antibodies was not affected by trypsin treatment of RRV at a concentration that enhances infectivity (data not shown). A peculiar characteristic of the plaque reduction assay with the anti-hemagglutinin hybridomas was that a small fraction (10 to 20%) of virus was not neutralized by any of the concentrations of ascites fluid tested.
We identified gene 4 of RRV as the gene which coded for the 82-kd protein by reacting selected monoclonal antibodies which precipitated the 82-kd protein ( Three monoclonal antlbodies had HI activity (Table 4 ) but did not precipitate the 82-kd protein (Fig. 2, lanes 4, 6, 7 , and 8, and Fig. 3 , lane 5). These three monoclonal antibodies immunoprecipitated a 38-kd band that migrated just ahead of the 42-kd major inner structural protein of RRV (Fig. 2 and 3) . Experiments with tunicamycin-treated cell lysates demonstrated that this band was glycosylated and that the non-glycosylated precursor protein was precipitated by the monoclonal antibodies in the tunicamycin-treated lysate (Fig. 3, lanes 6 and 8) . Cell culture supernatant fluid from these three monoclonal antibodies inhibited HA by the RRV, canine rotavirus, and to a lesser extent SA-11 (Table 4) . Unlike the hybridomas directed at the 82-kd protein, monoclonal cell culture supernatant fluid from these three hybridomas exhibited neutralizing activity against RRV (titer, 1:160 to 1:320; data not shown). Mouse ascites fluid derived from the three monoclonal antibodies (Table 5 ) exhibited high-titer neutralizing activity against the homologous RRV. Unlike the monoclonal antibodies to the 82-kd protein, these monoclonal antibodies also efficiently neutralized the serologically related canine and SA-11 rotaviruses. The P strain of human rotavirus, which is also serologically related to RRV (R. Wyatt, unpublished data), was neutralized by two of the three monoclonal antibodies ( Table  5 ). The serologically distinct bovine UK and human Wa strains were not neutralized. At dilutions of 1:2,000 or less the three monoclones to the 38-kd glycoprotein effected complete neutralization of RRV (100%o plaque reduction).
Since the monoclonal antibodies which immunoprecipitated the 38-kd glycoprotein reacted specifically with RRV and not UK rotavirus in solid-phase RIA (Table 3 , monoclones 954/159/ 33 and 954/96/18), we could use the same strategy to make gene-coding assignments for these monoclones as we had used for the monoclonal antibodies which immunoprecipitated the 82-kd protein. In previous studies we had shown that viral serotype was primarily a function of the eighth or ninth RNA segment, whereas viral hemagglutinin was coded for by the fourth RNA segment (9, 15, 16) . When tested in solid-phase RIA, the monoclonal antibodies against the 38-kd glycoprotein bound only to RRV x UK bovine rotavirus reassortants that were serotypically RRV, whether or not the reassortant hemagglutinated erythrocytes (Table 3 , monoclones 954/159/33 and 954/96/18). When the genotype of the reassortants was correlated with the monoclonal binding in solid-phase RIA, it was found that monoclonal antibody binding correlated with the presence in the reassortant of an eighth or ninth gene derived from RRV. These two genes could not be differentiated in the reassortants. These data indicated that the 38-kd glycoprotein is the product of one of these two gene segments.
Because the monoclonal antibodies directed at the 38-kd glycoprotein had HI activity but did not appear to bind to the viral hemagglutinin in 35S-labeled cell lysates or in solid-phase RIA, we tested these monoclonal antibodies for their capacity to inhibit HA by selected reassortants (Table 6 ). Monoclonal antibodies 954/145/55 and 952/147/3, which reacted with the 82-kd protein and tracked to the fourth gene product in solidphase RIA, had HI activity against all reassortant viruses irrespective of the reassortant neutralization serotype (bovine or simian). On the other hand, monoclonal antibodies 954/159/33 and 952/3/68, which precipitated the 38-kd protein and tracked to the eighth or ninth RRV gene product in RIA, had HI activity only when the reassortants exhibited the rhesus rotavirus neutralization serotype. The RRV HA activity of reassortants 28-1 and 85-2, which had the bovine serotype, was not inhibited by these monoclonal antibodies (Table 6 , monoclones 954/159/33 and 952/3/68). This suggests that the HI activity of these monoclonal antibodies was not mediated by direct interaction with the hemagglutinin. DISCUSSION We have recently shown by a genetic analysis of rotavirus reassortants that gene 4 of RRV codes for the viral hemagglutinin. In addition, the fourth gene product was associated with protease-enhanced plaque formation, whereas gene 8 or 9 coded for the primary neutralization determinant (15) . In the present work we have used monoclonal antibodies directed at two surface proteins of RRV to confirm and extend these findings. Because of previous difficulty in isolating monoclonal antibody to the outer capsid proteins of rotavirus, in these experiments we chose to use an HI test rather than RIA as our principal screening technique. With this strategy we were able to isolate and clone 39 separate hybridomas with a high level of HI activity. The majority of these monoclonal antibodies immunoprecipitated an 82-kd protein that could be shown to be the product of gene 4 of RRV. In addition, most of these monoclonal antibodies immunoprecipitated several smaller proteins ( Fig. 1 and 2 ) which are presumably tryptic cleavage products of the 82-kd primary gene product (5, 6) . The lysate used in these studies was harvested in the presence of a trypsin inhibitor, phenylmethylsulfonyl fluoride. Inhibition, however, appears to have been incomplete. The putative cleavage products seen in the RRV lysate are somewhat larger than those described by other workers (5, 6) . Of interest, none of the monoclonal antibodies precipitated a protein in the 20-to 30-kd range. Other workers have shown that the primary product of gene 4 is cleaved in vitro and in vivo into two pieces, a larger fragment and a smaller fragment in the 20-to 30-kd range (5, 6). Since our monoclonal antibodies were selected for their ability to inhibit HA, it is possible that this smaller cleavage fragment does not contain the HA domain of the molecule and hence was not immunoprecipitated.
The finding that ascites fluid containing high levels of monoclonal antibody directed at the 82-kd protein, the fourth gene product, had substantial neutralizing activity is of interest. Despite the demonstration by Hayes et al. (13) that several reovirus proteins can mediate viral neutralization, a similar finding with rotavirus was unexpected. Previous genetic studies of reassortants derived from human rotavirus strains Wa, W, and DS-1 had not demonstrated neutralizing activity segregating in association with gene 4 (9, 10, 16) . However, in these studies gene 4 of the human rotavirus could not be evaluated since it was not present in any of the cultivable reassortants (9, 10, 12, 16) . In addition, the antiserum used to characterize the UK virus and to select serotypic human reassortants came from guinea pigs immunized with the bovine Nebraska calf diarrhea virus. In retrospect it seems likely and fortunate that this antiserum, although highly cross-reactive with the UK bovine 38-kd glycoprotein, contained little or no neutralizing activity directed at the UK gene 4 (28) . The monoclonal antibodies directed at the rotavirus 82-kd protein all appear to be directed at antigenic domains with shared neutralization and HA activity. Whether these areas of the 82-kd protein are involved in tissue or host tropism remains to be determined. These monoclonal antibodies are apparently directed at a site distinct from the trypsin cleavage site, since neither inhibition of HA nor neutralization of the virus by gene 4 monoclonal antibodies appears to be affected by proteolytic activation of virus. Interestingly, monoclonal antibodies directed at the reovirus protein that has a biologically active proteolytic cleavage site (,ulc) do not neutralize infectivity (13) .
The three monoclonal antibodies directed to the 38-kd RRV glycoprotein each neutralized the virus to high titer. This was to be expected since previous studies by Bastardo et al., Killen and Dimmock, and Matsuno and Inouye had shown that hyperimmune monospecific antiserum to the 38-kd glycoprotein neutralizes rotavirus (1, 21, 24) . The demonstration that this protein is (15) and supports the translation studies of others (23, 25, 27 can be inhibited by steric interference due to the close proximity of two proteins on the viral surface (20) . The heterologous HI and neutralization patterns exhibited by the monoclonal antibodies to the 38-kd glycoprotein were similar to observations made with hyperimmune sera and clearly differed from data derived with monoclonal antibodies to the gene 4 product (canine rotavirus, Tables 1, 2, 4, and 5, for example). In the future, analysis of rotavirus HI and neutralization assays will have to take note of the fact that antibodies to two separate proteins are being measured in a single assay. The number of functional epitopes of the 38-kd glycoprotein was not investigated by us and will require the production of more monoclonal antibodies for thorough analysis. In unpublished studies we have isolated several monoclonal antibodies from mice immunized with Wa human rotavirus which cross-react with virtually all mammalian rotaviruses in solid-phase RIA. These monoclonal antibodies immunoprecipitate the 38-kd glycoprotein of Wa virus, as well as those of RRV and other mammalian rotaviruses (Fig. 3, lanes 7 and 8) . These same monoclonal antibodies do not neutralize Wa or RRV or inhibit RRV HA, and presumably they define a separate epitope on the rotavirus glycoprotein not involved in these functions. This epitope, in contrast to the epitope involved in virus neutralization, is antigenically cross-reactive among most mammalian rotaviruses.
The biological functions of several of the rotavirus outer capsid proteins in vitro are beginning to come into focus; however, the role of these proteins in vivo remains unexplored. It is interesting that both surface proteins exhibit type specificity. Perhaps the production of additional hybridomas will allow definition of epitopes with broader cross-reactivity on the two proteins. The relative importance to the host of an immune response to both the 82-and 38-kd proteins requires careful analysis in animal models and in humans. The mechanism of viral neutralization as mediated through the two proteins might well be different. Certainly it is not clear which of these two surface proteins (or both) is the primary determinant of tissue tropism and host range. Additional studies need to be done to determine which protein is primarily involved in cell binding and which is involved in cell penetration or exit from lysosomal vacuoles.
The availability of specific monoclonal antibodies should aid in elucidating some of these questions.
